Gradient Denervation Technologies
Gradient Denervation Technologies develops a device-based minimally invasive solution for the treatment of pulmonary hypertension with technology derived from an invention by clinicians from Stanford University. It is a privately held portfolio company of Sofinnova Partners, financed through the MD Start III Fund and based in Paris, France.
Sector
Medical Devices
Strategies
MD Start
Status
Live
Website
www.gradientdenervation.com
Related News
Gradient Denervation Technologies appoints Stanton Rowe to Board of Directors and receives FDA approval to expand early feasibility study
Gradient Denervation Technologies enrolls first patient in early feasibility study of pulmonary artery denervation system
Gradient Denervation Technologies closes €14m Series A led by Sabadell Asabys
Gradient Denervation Technologies enrolls initial patient in first-in-human study of pulmonary artery denervation technology
Gradient Denervation Technologies announces appointment of Martin Grasse as Chief Executive Officer
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.